The first marketed immunotherapeutic cytokine is IFN‐α for hairy cell leukemia which was approved in 1986.[1a] Subsequently, IL‐2 was approved for renal cancer and metastatic melanoma.[108] The ICD effect triggered by chemotherapy could be strengthened in combination with cytokines‐based immunotherapy, thus, potent immune responses were elicited to promote maturation of DCs /NK cells and increase the number of CTLs in the tumor environment,[109] which has been demonstrated to be a promising approach against melanoma.[110]. The gene discussed is IL2; the disease is neoplasm.